Tatva Chintan Pharma Chem Limited has informed the Exchange regarding Outcome of Board Meeting held on May 02, 2025.
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.5 pts more than Nifty Microcap 250 and 2.2 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Directors met on May 2, 2025, and approved the audited standalone and consolidated financial results for Q4 and FY ended March 31, 2025. Consolidated revenue from operations fell sharply to Rs 3,935.04 million from Rs 7,136.90 million in FY24, a drop of roughly 45% year-on-year. Consolidated profit after tax slumped to Rs 57.13 million from Rs 303.54 million, while standalone PAT came in at Rs 82.47 million (vs Rs 293.48 million). Operating cash flow remained positive at Rs 246.71 million on a consolidated basis. The Board recommended a final dividend of Rs 1 per share (10%) subject to shareholder approval, and appointed M/s TNT & Associates as Secretarial Auditor (5-year term), Zarna Thakar & Associates as Cost Auditor, and RSM Astute Consultech as Internal Auditor for FY26.
Sharply lower revenue and earnings point to continued business headwinds and pressure on profitability; the maintained dividend offers modest consolation, but shareholders should brace for weak near-term sentiment given the steep YoY decline in top line and bottom line.